Newsletter July 2011 - Safety of Tiotropium Respimat
A recent rapid review by the National Prescribing Centre has addressed the safety of Tiotropium Respimat in COPD. This includes reference to my editorial in the BMJ and shows the use of a Cates Plot to illustrate the absolute difference in risks found by Singh et al in the accompanying BMJ article. The relative and absolute differences in risk are contrasted in the editorial.